Price History
Feb 9, 2026 — May 20, 2026Investment Snapshot
- Trading 18% above Graham Number — above intrinsic value estimate
- Piotroski F-Score 6/9 — moderate financial health
- ROE of 21.4% — good return on equity
- Revenue declining 7% annually
Cabot Corporation Common Stock (CBT) is a Basic Materials company operating in Miscellaneous Chemical Products, listed on the NYSE , with a market capitalisation of $4.1 billion . Key value metrics: P/E ratio 12.1, P/B ratio 2.59, Piotroski F-Score 6 out of 9 (moderate financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Cabot Corporation Common Stock — Fundamental Analysis Summary
Cabot Corporation Common Stock (CBT) is currently trading 18% above its Graham Number of $66.70, suggesting the market price exceeds Benjamin Graham's intrinsic value estimate. The stock carries a reasonable trailing P/E ratio of 12.1x.
On financial health, CBT shows a moderate Piotroski F-Score of 6/9, and strong return on equity of 21.4% (sector average: -1.2%), and manageable leverage with a debt-to-equity ratio of 0.66.
StockPik's composite Value Score for CBT is 87/100 — placing it in undervalued territory. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
CBT reports a moderate gross margin of 25.1% (sector average: 33.0%) and a solid operating margin of 16.3%.
CBT shows revenue declining at 7% year-over-year, with earnings declining at 13%.
CBT pays a modest dividend yield of 2.3%.